RGX-314 is under development for the treatment of wet age-related macular degeneration, diabetic retinopathy, diabetic macular edema and other chronic retinal conditions. It is administered through ...

The drug candidate was also under development for the treatment of cerebral amyloid angiopathy, familial AD (Alzheimer’s disease) and traumatic brain injury, inclusion body myositis and age-related ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular edema ...

VESC display Roche's Tecentriq single-drug first-line treatment for non-small cell lung cancer reaches OS endpoint Johnson & Johnson acquires Hemera's gene ...

INR:1974. scrum poker️ The real challenge that DRG poses to private hospitals Two blockbuster generic drugs from Qilu were approved: albumin paclitaxel for injec ...

and pharmacokinetics in treating neovascular age-related macular degeneration (nAMD), both as a first-line therapy and after ...

INR:6434. betfair odds explained Gilead and Vir reach collaboration to develop curative treatment for hepatitis B Allergan files for approval of abicipar f ...

Implementation plan for the construction of a team of professional drug inspectors, with 5 inspection offices Roche's Phase 3 clinical results of long-acting bispecific antibody are positive for the t ...

bet winner app 『Pharmaceutical Headlines』Hubei launches a large-scale inspection of pharmacies and the curtain has been raised on comprehensive drug monitoring Medical Talent Recruitment (Updated on 9 ...

Class 1 new drugs approved for clinical trials, from Sanofi, Impa Pharmaceuticals and other companies \| CDE Weekly Positive ...

Investigators conducted a meta-analysis of randomized controlled trials to assess the efficacy and safety of brolucizumab ...

INR:3598. football court measurement in meters Roche's Phase 3 clinical results of long-acting bispecific antibody are positive for the treat ...